Data Insights

Apatinib mesylate by Elevar Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Apatinib mesylate by Elevar Therapeutics for Synovial Sarcoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Synovial Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Synovial Sarcoma

Data Insights

Apatinib mesylate by Elevar Therapeutics for Melanoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Melanoma

Data Insights

Apatinib mesylate by Elevar Therapeutics for Leiomyosarcoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Leiomyosarcoma

Data Insights

Apatinib mesylate by Elevar Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Pre-Registration for Hepatocellular Carcinoma. According to GlobalData, Pre-Registration...

Data Insights

Apatinib mesylate by Elevar Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Data Insights

Apatinib mesylate by Elevar Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According...

Data Insights

Apatinib mesylate by Elevar Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Data Insights

Apatinib mesylate by Elevar Therapeutics for Synovial Sarcoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Synovial Sarcoma. According to GlobalData,...

Data Insights

Apatinib mesylate by Elevar Therapeutics for Melanoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase...

Data Insights

Apatinib mesylate by Elevar Therapeutics for Leiomyosarcoma: Likelihood of Approval

Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase...